Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2004

View Archived Issues

Genetic discovery may lead to new treatments for muscular dystrophies

Promising triterpenoid derivative for the treatment of IBD

Crucell and IAVI to use AdVac technology to develop AIDS vaccine

Rectogesic approved in U.K.

Research in stimulating immune responses of juvenile diabetics

Therapeutic effects of DPP-IV inhibition with LAF-237 in patients with type 2 diabetes

Novel synthetic immunomodulator reduces graft rejection in vivo

New dopamine D3 modulators identified at Abbott

AstraZeneca and NPS present novel group I mGluR antagonists

Aventis scientists describe new NHE-3 inhibitors and their use

Bayer patent covers new PGI2 antagonists for urological disorders and other uses

New RXR agonists prepared and tested by Allergan researchers

BMS scientists design novel thyroid receptor agonists for obesity, skin disorders, etc.

New glucocorticoid receptor modulators claimed by Merck

Lilly scientists describe novel GR and MR modulators and their use

New antidepressant safety information recommended for pediatric population

Gliadel approved for new indication in Europe

Boston Life Sciences' phase I Axosine study on hold pending further data

First two cohorts enrolled in phase II study of ANA-380 for HBV

Phase IIIb results support use of Xyrem as first-line therapy for narcolepsy

CA4P investigated in combination with cisplatin in phase I cervical cancer study

Pfizer achieves a number of key objectives during Q2

Antigen Express collaborates on melanoma vaccine development

Nuvelo and Kirin Brewery expand research and development collaboration

Merger between Genzyme and Ilex Oncology expected to close in Q4

ACP-103 reduces side effects of haloperidol

Patient enrollment completed in a clinical trial with Progenta in uterine fibroids

CVT-4325 improves systolic function and reduces myocardial oxygen consumption in dogs with CHF

Clinical trials confirm the efficacy and safety of efalizumab in chronic plaque psoriasis

A bacterial regulatory lipopeptide shows promise in asthma and allergic rhinitis

Ziopharm licenses new class of organic arsenicals from M.D. Anderson

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...